Quick Answer
Context Therapeutics Inc. reported Earnings Per Share Diluted of $0.38 (loss) per share for the year ending 2025.
- Context Therapeutics Inc. showed an increase of +17.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Context Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $2.52 (loss) per share | Q1 2021: $2.55 (loss) per share | Q2 2021: $14.18 (loss) per share | Q3 2021: $4.00 (loss) per share | Q1 2022: $0.22 (loss) per share | Q2 2022: $0.25 (loss) per share | Q3 2022: $0.24 (loss) per share | Q1 2023: $0.40 (loss) per share | Q2 2023: $0.31 (loss) per share | Q3 2023: $0.37 (loss) per share | Q1 2024: $0.23 (loss) per share | Q2 2024: $0.04 (loss) per share | Q3 2024: $0.22 (loss) per share | Q1 2025: $0.05 (loss) per share | Q2 2025: $0.09 (loss) per share | Q3 2025: $0.10 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Context Therapeutics Inc.'s Earnings Per Share Diluted has grown by 90.4%.
- Historical annual values: Fiscal year 2025: $0.38 (loss) per share | Fiscal year 2024: $0.46 (loss) per share | Fiscal year 2023: $1.50 (loss) per share | Fiscal year 2022: $0.93 (loss) per share | Fiscal year 2021: $3.69 (loss) per share | Fiscal year 2020: $3.96 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: